Cancer by Shiels, Meredith S. et al.
Cancer Stage at Diagnosis in HIV-infected People and 
Transplant Recipients
Meredith S. Shiels, PhD1, Glenn Copeland, MBA2, Marc T. Goodman, PhD3, Janna Harrell, 
MS4, Charles F. Lynch, MD, PhD5, Karen Pawlish, ScD6, Ruth M. Pfeiffer, PhD1, and Eric A. 
Engels, MD1
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD
2Michigan Cancer Surveillance Program, Michigan Department of Community Health, Lansing, MI
3Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA
4Utah Cancer Registry, Salt Lake City, UT
5Department of Epidemiology, College of Public Health, The University of Iowa, Iowa City, IA
6New Jersey State Cancer Registry, New Jersey Department of Health, Trenton, NJ
Abstract
Background—It is unknown whether immunosuppression results in more aggressive, advanced 
stage cancers. As cancer stage is influenced both by tumor biology and medical surveillance, we 
assessed cancer stage in HIV-infected individuals and solid organ transplant recipients, two 
immunosuppressed groups with differences in healthcare utilization.
Methods—We used data on all cases of 15 cancer types, diagnosed during 1996–2010 in two 
studies that linked U.S. cancer registries to HIV and transplant registries. Odds ratios (ORs) for 
advanced (vs. local) disease were estimated comparing HIV and transplant populations to 
immunocompetent people in polytomous logistic regression models, adjusted for age, sex, race, 
registry and year.
Results—A total of 8,411 of 4.5 million cancer cases occurred in HIV-infected people, and 
7,322 of 6.4 million cancer cases occurred in transplant recipients. Compared to 
immunocompetent people with cancer, HIV-infected people were more likely to be diagnosed 
with distant stage lung (OR=1.13), female breast (OR=1.99), and prostate cancers (OR=1.57), 
while transplant recipients had fewer distant stage lung (OR=0.54), female breast (OR=0.75) and 
prostate cancers (OR=0.72). Both immunosuppressed populations had a shift toward advanced 
stage melanoma (ORs: HIV=1.97; transplant=1.82) and bladder cancer (ORs: HIV=1.42; 
transplant=1.54).
Conclusions—Bladder cancer and melanoma were more likely to be diagnosed at non-local 
stage in both HIV-infected people and transplant recipients, suggesting a role of 
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immunosuppression in their progression. Additionally, we observed a shift for some common 
cancers toward later stages in HIV-infected individuals and toward earlier stages in transplant 
recipients, consistent with differential access to medical care or surveillance.
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Individuals with suppressed immune systems are at increased risk for developing a number 
of cancers, particularly those associated with viral infections. Solid organ transplant 
recipients and people infected with human immunodeficiency virus (HIV) are two 
populations with immunosuppression, predominantly related to deficits in T-cell function, 
and have elevated cancer risks (1). However, it is unknown whether immunosuppression 
also increases tumor aggressiveness, so that malignancies progress particularly quickly to 
advanced disease and death. The stage of cancer at the time of diagnosis reflects whether the 
tumor is localized, has spread to regional tissues or metastasized to more distant sites. Thus, 
assessing cancer stage in these populations may provide insight into the effect of 
immunosuppression on cancer progression.
Prior research on cancer stage in HIV and transplant populations has been limited. One 
study, which compared cancers from an international transplant registry to cases from the 
U.S. general population, found that transplant recipients presented at later stages (2). Studies 
of HIV-infected people have demonstrated advanced stages at diagnosis for colorectal 
cancer (3;4) and lung cancer (5), but others had discrepant findings (6;7). No prior study has 
assessed cancer stage for multiple cancer sites among both HIV-infected individuals and 
transplant recipients.
Though both the HIV-infected and transplant recipient populations experience deficits in 
cell-mediated immune function, the characteristics of these populations differ. HIV-infected 
people are more likely to be uninsured (8), affected by poverty (9), and more likely to 
exhibit social behaviors, such as drug use, that interfere with utilization of health services, 
including cancer screening. In contrast, health insurance is a requirement for organ 
transplantation, and transplant recipients undergo frequent monitoring of 
immunosuppressive medications and graft function. The parallel comparison of cancer stage 
in these two immune suppressed populations is important, because stage at diagnosis is 
influenced both by the tumor biology and the point during the course of cancer development 
when the tumor is first detected. People who receive less healthcare are more likely to be 
diagnosed with later stage disease, particularly for screen-detectable cancers (10), while 
people receiving increased surveillance are more likely to be diagnosed with earlier stage 
disease. Thus, a similar shift towards advanced stage in both populations would be best 
explained by an effect of immunosuppression on malignancy biology. Tumor grade (i.e., 
degree of differentiation manifested by tumor cells) is another marker of tumor 
aggressiveness that may be less impacted by the timing of cancer diagnosis; however, grade 
is not systematically ascertained for all tumor sites.
In the current study, we compared the stages of cancers diagnosed in HIV-infected people 
and transplant recipients with the stages for other cancer patients (i.e., “immunocompetent” 
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patients), using data from two large registry linkage studies. We also evaluated the 
distribution of tumor grade for select cancer sites. Additionally, among individuals with 
cancer within each population, we assessed whether indicators reflecting the degree of 
immunosuppression were associated with advanced stage.
Methods
Cancers were ascertained from the National Cancer Institute’s HIV/AIDS Cancer Match 
(HACM) (www.hivmatch.cancer.gov) and Transplant Cancer Match (TCM) Studies 
(www.transplantmatch.cancer.gov). Briefly, the HACM Study is a linkage of U.S. HIV and 
cancer registries (1980–2010), and the TCM Study is a linkage of the U.S. Scientific 
Registry of Transplant Recipients (SRTR) and cancer registries (1987–2010). Automated 
matching software was used to link HIV and cancer registries, and the SRTR and cancer 
registries, based on social security, name, date of birth and sex. Matches identified by the 
software were confirmed through clerical review. Fourteen regions from each study were 
included in this analysis. From cancer registries, we identified all cases in the general 
population of the most common solid tumors (i.e., oral cavity/pharynx, stomach, colorectum, 
anus, liver, pancreas, lung, melanoma, female breast, cervix, uterus, prostate, bladder, 
kidney and thyroid), and linkage with HIV registries and the SRTR identified cases that 
occurred in HIV-infected people or among transplant recipients, respectively. Cancer 
diagnoses were classified using a previously described classification scheme (11). We 
restricted to cancers diagnosed during 1996–2010, the time period following introduction of 
highly active antiretroviral therapy to treat HIV.
Stage at cancer diagnosis (i.e., in situ, localized, regional, distant) was categorized using 
Surveillance, Epidemiology, and End Results (SEER) summary stage (i.e., a combination, 
based on diagnosis year, of SEER summary stage 1977 and 2000 and derived SEER 
summary stage 2000). All cancer sites were limited to invasive disease, except for bladder 
cancer, female breast cancer and melanoma, where in situ cases were also considered. We 
also assessed cancer grade (i.e., well differentiated, moderately differentiated, poorly 
differentiated and undifferentiated) for a subset of cancers where grade information was 
available on >70% of cases (i.e., oral cavity/pharynx, stomach, colorectum, uterus, prostate, 
and bladder cancers). New York and Michigan registries were excluded from the grade 
analysis due to a larger fraction of missing information. Liver cancers occurring among liver 
transplant recipients were excluded to avoid counting cancers in the native liver that were 
present prior to transplantation. Male breast cancers were excluded.
Statistical Analysis
To provide context for our results, we estimated standardized incidence ratios (SIRs) for 
each cancer, comparing observed cancer cases in HIV-infected people or transplant 
recipients with expected cases, calculated by applying general population cancer rates from 
the cancer registries, standardized by age, sex, race, calendar year and registry to the HIV 
and transplant populations. SIRs represent the relative risk of each cancer in the HIV or 
transplant population, compared to the general population.
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Next, we assessed the associations of HIV and transplantation with cancer stage in separate 
analyses that included all cases captured by the cancer registries of the HACM and TCM 
Studies, respectively. We utilized polytomous logistic regression models to assess the 
association between HIV (yes/no) or transplant status (yes/no) with stage at diagnosis (local 
as reference category). Regional and distant stages were collapsed for cancers with <10 
distant stage cases. All models were adjusted for age, sex, race (white, black and other), 
calendar year and registry. Proportional odds logistic regression models were used to 
estimate p-values for trend across stages. These models were also used to assess grade as the 
outcome (well-differentiated as the reference category). Grade categories with <10 cases 
were collapsed with adjacent categories.
For our stage analysis, we interpreted our results based on the consistency of our findings 
across both HIV and transplant populations, focusing on p-values for trend across stages to 
assess statistically significant shifts in stage at diagnosis. When stage was more advanced 
only among HIV-infected people, and/or stage was less advanced only among transplant 
recipients, we interpreted the results to indicate that differences in surveillance or screening 
were the likely explanation. We interpreted the evidence as supporting a role of 
immunosuppression in cancer progression when stage was more advanced in both 
populations. Finally, we assessed the association between indicators of immunosuppression 
(i.e., AIDS status and time since transplant) with stage at diagnosis (regional/distant vs. 
local) using logistic regression, adjusting for age and sex. All analyses were carried out with 
SAS version 9.3 (Cary, NC).
Results
We included a total of 4,471,704 and 6,435,000 cancer cases from the HACM and TCM 
Studies, respectively (Table 1). Of these cases, 8,411 (0.19%) were HIV-infected at the time 
of cancer diagnosis and 7,322 (0.11%) were transplant recipients. Compared to cancer cases 
without HIV, HIV-infected cases were more likely to be male, black, and 30–49 years old. 
Cancer cases with a transplant were more likely to be male, black, and aged 50–69 years 
than cancer cases who had not had a transplant. These differences generally reflect 
demographic characteristics of the U.S. HIV and transplant populations. Of the cancers 
included, lung, anal and cervical cancers were the most common cancers in people with 
HIV, while lung, prostate and kidney cancers were the most common in transplant 
recipients.
Compared to the general population, the risk of several cancers was significantly elevated 
(i.e., oral cavity/pharynx, anus and lung) or decreased (i.e., uterine corpus, female breast, 
and prostate) in both HIV-infected people and transplant recipients (Figure 1; Supplemental 
Table 1). In contrast, the risks of stomach, colorectal, pancreatic, bladder, kidney, and 
thyroid cancers and melanoma were increased only in transplant recipients, and the risks of 
liver and cervical cancers were increased only in HIV-infected people. HIV-infected people 
had decreased risks of colorectal, thyroid and bladder cancers.
For several cancers, we observed trends toward advanced stage disease only in HIV-infected 
people, and/or trends toward local stage disease in transplant recipients, compared to 
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immunocompetent patients (i.e., those without HIV or a transplant, respectively; Table 2), 
likely indicating a role for differences in surveillance or screening. For lung cancer, HIV-
infected people were somewhat more likely to present with distant stage cancer (odds ratio 
[OR]=1.13, 95%CI 0.98–1.29, p-trend=0.08), and transplant recipients were less likely to 
present with distant stage cancer (OR=0.54, 95%CI 0.48–0.61, p-trend<0.001). A similar 
pattern was seen for female breast cancer (HIV: OR=1.99, 95%CI 1.40–2.83, p-trend=0.008; 
transplant: OR=0.75; 95%CI 0.47–1.19, p-trend<0.001). For prostate cancer, HIV-infected 
individuals were more likely to present with distant stage disease (OR=1.57, 95%CI 1.10–
2.25), but less likely to have regional stage disease (p-trend=0.21); transplant recipients were 
less likely to present with distant stage prostate cancer (OR=0.72, 95%CI 0.51–1.04, p-
trend<0.001). Additionally, compared with immunocompetent patients, HIV-infected 
individuals had a shift toward distant stage cervical cancers (p-trend=0.01), and transplant 
recipients had a shift toward local stage kidney (p-trend<0.001) and oral cavity/pharynx 
cancers (p-trend<0.001).
In contrast, a role for immunosuppression was suggested for melanoma and bladder cancer, 
because both HIV-infected people and transplant recipients were more likely to be 
diagnosed with advanced stage disease (i.e., regional or distant stage disease) than 
immunocompetent people (Table 2). For melanoma, HIV-infected individuals were more 
likely to be diagnosed with distant stage disease (OR: 2.43; 95%CI 1.45–4.06; p-
trend<0.001); and transplant recipients were more likely to be diagnosed with regional stage 
disease (OR=2.01; 95%CI 1.53–2.65). Though the OR for distant stage melanoma among 
transplant recipients was not statistically significant, a trend toward more advanced stage 
disease was present (p-trend=0.04). HIV-infected individuals were more likely to be 
diagnosed with regional/distant stage bladder cancer (OR=1.42; 95%CI 0.88–2.30; p-
trend=0.001), and transplant recipients were more likely to be diagnosed with distant stage 
bladder cancer (OR=1.80; 95%CI 1.16–2.77; p-trend=<0.0001).
For anal cancer, there was a trend toward local stage for both groups (both p-trends<0.05). 
No associations were observed between either HIV infection or transplant and stage for 
cancers of the stomach, colorectum, liver, pancreas, uterus or thyroid (Table 2).
In an analysis restricted to HIV-infected cancer cases, no significant associations were 
observed between an AIDS diagnosis and regional/distant cancer stage for any cancer site 
(Supplemental Table 2). In an analysis restricted to cancer cases among transplant 
recipients, tumors diagnosed early after transplant were more likely to be local stage for 
female breast cancer (p-trend=0.04), and distant/regional stage for melanoma (p-trend=0.01; 
Supplemental Table 3). Compared to recipients diagnosed with melanoma 10+ years after 
transplant, a strongly increased likelihood of regional/distant disease was observed in 
recipients diagnosed <1 year (OR=2.67; 95%CI 0.75–9.47) and 1–4 years (OR=3.92; 95%CI 
1.32–11.7) after transplant.
As shown in Table 3, both HIV-infected people and transplant recipients were more likely to 
be diagnosed with higher grade bladder cancers than immunocompetent people 
(undifferentiated vs. well differentiated: HIV: OR=2.48; 95%CI 1.43–4.32; transplant: 
OR=1.74; 95%CI 1.15–2.65). In contrast, both HIV and transplantation were associated with 
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a shift toward more well differentiated oral cavity/pharynx cancers (p-trends<0.05), and 
prostate cancer (p-trends<0.05).
Discussion
HIV-infected people and solid organ transplant recipients have an elevated risk of cancer 
(1), but it has been unclear whether immunosuppression also affects the clinical behavior of 
cancer and accelerates progression. Here we have shown that several cancer sites are shifted 
toward more advanced disease only among HIV-infected individuals and/or toward less 
advanced disease only among transplant recipients (i.e., oral cavity/pharynx, lung, female 
breast, cervix, prostate, and kidney), which is probably most consistent with differences 
between these populations in medical care or surveillance. In contrast, only bladder cancer 
and melanoma were more likely to be diagnosed at regional/distant stage in both the HIV 
and transplant populations, potentially indicating a role for immunosuppression.
HIV-infected individuals and solid organ transplant recipients have been studied to 
understand the role of immunity in cancer development. Immunosuppression is induced in 
HIV-infected people when HIV infects and destroys CD4+ T helper cells and other cell 
types, and is induced in transplant recipients through the administration of medications 
designed to suppress the cell-mediated immune system and prevent rejection of the 
transplanted organ. The striking similarity in the spectrum of cancer in these two 
populations speaks to the importance of defects in T-cell immunity in the etiology of many 
cancer sites. Immunosuppression is particularly relevant for cancers caused by viral 
infections (1), as an intact immune system is needed to control oncogenic infections and 
virally infected pre-cancerous cells.
Despite similarities in immunosuppression, these populations differ in other characteristics. 
For example, HIV-infected individuals are disproportionately affected by poverty (9), which 
results in decreased access or utilization of health care, while transplant recipients are 
followed closely after transplantation, resulting in heightened medical surveillance. Further, 
in the U.S., HIV-infected people are less likely to have health insurance; one study of HIV-
infected individuals in care reported that 28.4% were uninsured, compared to 2.6% of liver 
transplant recipients in another study (8;12).
Differences in the frequency and comprehensiveness of medical surveillance likely provide 
the basis for some differences in cancer stage that we observed between these populations. 
For example, transplant recipients had more local stage prostate and female breast cancers, 
while HIV-infected people had more distant stage prostate and female breast cancers. As 
prostate-specific antigen (PSA) testing and mammography lead to early cancer detection, 
stage shifts could be driven by differential screening (13;14). Similarly, HIV-infected 
women were more likely to be diagnosed with distant stage cervical cancer, which could 
represent a failure in cervical Pap smear screening. Though the Centers for Disease Control 
and Prevention recommends semi-annual Pap testing in the year after HIV diagnosis 
followed by annual testing for HIV-infected women, many women fail to receive screening 
or do not follow up after an abnormal Pap test (15;16). In a similar way, the down-staging of 
lung and kidney cancers in transplant recipients could be due to incidental detection through 
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radiological imaging during medical follow-up. Our suggestive finding of a later stage at 
lung cancer diagnosis in HIV-infected individuals could indicate delayed diagnosis. These 
results highlight the need for HIV clinicians to be alert to the possible presence of lung 
cancer and send HIV-infected patients for appropriate testing if they present with lung 
cancer symptoms.
These findings are thus consistent with health disparities among HIV-infected people, who 
are also less likely to receive appropriate cancer treatment (17) and more likely to die from 
their cancer diagnoses (18). Targeted efforts should be made to ensure that HIV-infected 
individuals receive comprehensive medical care that includes cancer prevention counseling 
and appropriate cancer screening. Screening in HIV-infected people may explain our 
findings for anal cancer, which was diagnosed at earlier stages in HIV-infected people, 
because anal Pap testing has been advocated for HIV-infected men who have sex with men 
(19). In additional analyses (not shown), we observed a shift toward earlier stage disease 
among HIV-infected men (p-trend<0.0001), but not women (p-trend=0.41), which may 
reflect this pattern in screening. It is unclear whether anal cancer screening could explain the 
downward stage shift in transplant recipients.
Our results showed a shift towards advanced stage disease for bladder cancer and melanoma 
in both HIV-infected people and transplant recipients. Though melanoma and bladder cancer 
risks are only elevated in the transplant population, later stages may indicate that an intact 
immune system plays a role in controlling the spread of these malignancies. 
Immunotherapies are used to treat melanoma, including T-cell agonists and drugs that target 
immune checkpoints (20). Further supporting the importance of immunity, among transplant 
recipients we observed that non-local cancers were most frequent in the first several years 
after transplantation. Transplant recipients experience the most intense immunosuppression 
during this period, and these results are consistent with prior analyses showing that the 
melanoma risk is greatest in the years immediately following transplantation (21).
Immunosuppression likely also contributes to bladder cancer metastasis (22). Bacillus 
Calmette-Guérin (BCG), a live attenuated strain of Mycobacterium bovis, is a standard 
treatment for intermediate-risk and high-risk non-muscle invasive bladder cancers (23). 
BCG establishes a local infection in the bladder, inducing a strong immune response, which 
has been shown to help prevent recurrence and tumor progression (24).
Our analyses of cancer grade provided a complementary perspective for some cancers. 
Grade is a metric that assesses how closely a tumor resembles the tissue of origin, and lack 
of differentiation is associated with higher mortality. Grade is less affected than stage by the 
timing of diagnosis along the continuum of cancer development. However, grade may be 
more subjective than cancer stage (25), and it is not uniformly collected. Bladder cancers 
diagnosed in both the HIV-infected and transplant populations were more poorly 
differentiated, providing further evidence for a biological role of immunosuppression in the 
clinical features of bladder cancer. Likewise, grade was more likely to be well differentiated 
for prostate cancer in transplant recipients, paralleling our findings showing a favorable shift 
in cancer stage. Finally, both HIV-infected people and transplant recipients were more likely 
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to have well differentiated cancers of the oral cavity/pharynx, perhaps indicating less 
aggressive tumors in immunosuppressed populations.
The main strength of this study is the availability of large and representative samples of 
cancer cases from the HIV-infected and transplant recipient populations in the U.S. This 
allowed us to systematically evaluate the stage distribution in these populations for the first 
time across 15 cancer sites. Given the shared mechanism of immunosuppression, but 
differences in access to medical care and cancer surveillance between these two populations, 
we were able to make inferences about the role of immunosuppression vs. detection in 
cancer stage. Our study was nonetheless limited by the information collected by population-
based registries. Therefore, we were unable to consider important factors, such as cigarette 
smoking, medical care, cancer screening, and molecular tumor characteristics that may also 
be related to progression and prognosis. Further, it is likely that there is some 
misclassification of the HIV and transplant status of some cancer cases due to the imperfect 
sensitivity of the linkages; however, we do not believe that these differences were 
differential by stage or grade, and thus they should not have biased the results. Finally, due 
to multiple cancers studied, it is possible that some of our results are false positives due to 
chance.
In conclusion, we have documented that bladder cancers and melanoma are more likely to 
be diagnosed at an advanced stage in both HIV-infected people and transplant recipients, 
indicating a potential role of immunity in the progression of both malignancies. In addition, 
we observed a shift for some common cancers toward later stages in HIV-infected people 
and toward earlier stages in transplant recipients, consistent with differences in medical 
surveillance and cancer screening. The advanced stage of cancers in HIV-infected people 
indicates a need for more comprehensive cancer prevention and early detection strategies for 
this population.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgements
This research was supported in part by the Intramural Research Program of the National Cancer Institute.
The authors gratefully acknowledge the support and assistance provided by individuals at the following HIV/AIDS 
and cancer registries: California, Colorado, Connecticut, Washington DC, Florida, Georgia, Hawaii, Illinois, Iowa, 
Los Angeles, Massachusetts, Maryland, Michigan, New Jersey, New York, North Carolina, Seattle, Texas, and 
Utah, and by individuals at the Health Resources and Services Administration (Monica Lin) and the SRTR (Ajay 
Israni, Bertram Kasiske, Paul Newkirk, Jon Snyder). We also thank Timothy McNeel, David Castenson, Matthew 
Chaloux, Michael Curry, and Ruth Parsons at Information Management Services for programming support.
The following cancer registries were supported by the SEER Program of the National Cancer Institute: California 
(contracts HHSN261201000036C, HHSN261201000035C, and HHSN261201000034C), Connecticut 
(HHSN261201000024C), Hawaii (HHSN261201000037C, N01-PC-35137, and N01-PC-35139), Iowa 
(HSN261201000032C and N01-PC-35143), New Jersey (HHSN261201300021I, N01-PC-2013-00021), Seattle-
Puget Sound (N01-PC-35142), and Utah (HHSN261201000026C). The following cancer registries were supported 
by the National Program of Cancer Registries of the Centers for Disease Control and Prevention: California 
(agreement 1U58 DP000807-01), Colorado (U58 DP000848-04), Georgia (5U58DP003875-01), Illinois 
(5U58DP003883-03), Maryland (U58DP12-1205 3919-03), Michigan (5U58DP003921-03), New Jersey (5U58/
DP003931-02), New York (U58DP003879), North Carolina (U58DP000832) and Texas (5U58DP000824-04). 
Shiels et al. Page 8













Additional support was provided by the states of California, Colorado, Connecticut, Illinois, Iowa, Massachusetts 
(Massachusetts Cancer Prevention and Control Cooperative Agreement 5458DP003920), New Jersey, New York 
(including the Cancer Surveillance Initiative), Texas, and Washington, as well as the Fred Hutchinson Cancer 
Research Center in Seattle, WA. The following HIV registries were supported by HIV Incidence and Case 
Surveillance Branch of the Centers for Disease Control and Prevention, National HIV Surveillance Systems: 
Colorado, Connecticut (5U62PS001005-05), Washington DC (5U62PS004015), Michigan (5U62PS004011-02), 
and New Jersey (U62PS004001-2).
The views expressed in this paper are those of the authors and should not be interpreted to reflect the views or 
policies of Health Resources and Services Administration or the SRTR. During the initial period when registry 
linkages were performed, the SRTR was managed by Arbor Research Collaborative for Health in Ann Arbor, MI 
(contract HHSH234200537009C); beginning in September 2010, the SRTR was managed by Minneapolis Medical 
Research Foundation in Minneapolis, MN (HHSH250201000018C).
Reference List
1. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/
AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007; 
370:59–67. [PubMed: 17617273] 
2. Miao Y, Everly JJ, Gross TG, et al. De novo cancers arising in organ transplant recipients are 
associated with adverse outcomes compared with the general population. Transplantation. 2009; 
87:1347–1359. [PubMed: 19424035] 
3. Berretta M, Cappellani A, Di BF, et al. Clinical presentation and outcome of colorectal cancer in 
HIV-positive patients: a clinical case-control study. Onkologie. 2009; 32:319–324. [PubMed: 
19521118] 
4. Chapman C, Aboulafia DM, Dezube BJ, Pantanowitz L. Human immunodeficiency virus-associated 
adenocarcinoma of the colon: clinicopathologic findings and outcome. Clin.Colorectal Cancer. 
2009; 8:215–219. [PubMed: 19822512] 
5. Brock MV, Hooker CM, Engels EA, et al. Delayed diagnosis and elevated mortality in an urban 
population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr. 
2006; 43:47–55. [PubMed: 16936558] 
6. Shiels MS, Cole SR, Mehta SH, Kirk GD. Lung cancer incidence and mortality among HIV-infected 
and HIV-uninfected injection drug users. J.Acquir.Immune.Defic.Syndr. 2010; 55:510–515. 
[PubMed: 20838223] 
7. Sigel K, Wisnivesky J, Gordon K, et al. HIV as an independent risk factor for incident lung cancer. 
AIDS. 2012; 26:1017–1025. [PubMed: 22382152] 
8. Yehia BR, Fleishman JA, Agwu AL, Metlay JP, Berry SA, Gebo KA. Health Insurance Coverage 
for Persons in HIV Care, 2006–2012. J Acquir.Immune.Defic.Syndr. 2014; 67:84–90. [PubMed: 
24872131] 
9. Denning P, DiNenno E. Communities in crisis: Is there a generalized HIV epidemic in impoverished 
urban areas of the United States? 2014. Centers for Disease Control and Prevention. 2014 Aug 14.
10. Walker GV, Grant SR, Guadagnolo BA, et al. Disparities in stage at diagnosis, treatment, and 
survival in nonelderly adult patients with cancer according to insurance status. J Clin.Oncol. 2014; 
32:3118–3125. [PubMed: 25092774] 
11. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency 
virus in the United States. Int J Cancer. 2008; 123:187–194. [PubMed: 18435450] 
12. Glueckert LN, Redden D, Thompson MA, et al. What liver transplant outcomes can be expected in 
the uninsured who become insured via the Affordable Care Act? Am J Transplant. 2013; 13:1533–
1540. [PubMed: 23659668] 
13. Shiels MS, Goedert JJ, Moore RD, Platz EA, Engels EA. Reduced risk of prostate cancer in U.S. 
Men with AIDS. Cancer Epidemiol Biomarkers Prev. 2010; 19:2910–2915. [PubMed: 20837717] 
14. Preston-Martin S, Kirstein LM, Pogoda JM, et al. Use of mammographic screening by HIV-
infected women in the Women's Interagency HIV Study (WIHS). Prev.Med. 2002; 34:386–392. 
[PubMed: 11902857] 
Shiels et al. Page 9













15. Rahangdale L, Sarnquist C, Yavari A, Blumenthal P, Israelski D. Frequency of cervical cancer and 
breast cancer screening in HIV-infected women in a county-based HIV clinic in the Western 
United States. J Womens Health (Larchmt.). 2010; 19:709–712. [PubMed: 20201703] 
16. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and 
treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations 
from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious 
Diseases Society of America. MMWR Recomm.Rep. 2009; 58:1–207.
17. Suneja G, Shiels MS, Angulo R, et al. Cancer Treatment Disparities in HIV-Infected Individuals in 
the United States. J Clin.Oncol. 2014; 32:2344–2350. [PubMed: 24982448] 
18. Coghill AE, Shiels MS, Suneja G, Engels EA. Elevated Cancer-Specific Mortality among HIV-
infected Patients in the U.S. 2014 Submitted. 2014. 
19. Wells JS, Holstad MM, Thomas T, Bruner DW. An integrative review of guidelines for anal cancer 
screening in HIV-infected persons. AIDS Patient.Care STDS. 2014; 28:350–357. [PubMed: 
24936878] 
20. McDermott D, Lebbe C, Hodi FS, et al. Durable benefit and the potential for long-term survival 
with immunotherapy in advanced melanoma. Cancer Treat.Rev. 2014; 40:1056–1064. [PubMed: 
25060490] 
21. Vajdic CM, van Leeuwen MT, Webster AC, et al. Cutaneous melanoma is related to immune 
suppression in kidney transplant recipients. Cancer Epidemiol.Biomarkers Prev. 2009; 18:2297–
2303. [PubMed: 19622722] 
22. Zhang H, Chin AI. Role of Rip2 in development of tumor-infiltrating MDSCs and bladder cancer 
metastasis. PLoS.One. 2014; 9:e94793. [PubMed: 24733360] 
23. Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial 
carcinoma of the bladder: update 2013. Eur.Urol. 2013; 64:639–653. [PubMed: 23827737] 
24. Brincks EL, Risk MC, Griffith TS. PMN and anti-tumor immunity--the case of bladder cancer 
immunotherapy. Semin.Cancer Biol. 2013; 23:183–189. [PubMed: 23410637] 
25. van Rhijn BW, van Leenders GJ, Ooms BC, et al. The pathologist's mean grade is constant and 
individualizes the prognostic value of bladder cancer grading. Eur.Urol. 2010; 57:1052–1057. 
[PubMed: 19765886] 
Shiels et al. Page 10













Figure 1. Relative risks of cancer in people with HIV and in transplant recipients compared to 
the general population
Standardized incidence ratios (SIRs) and 95% confidence intervals comparing cancer risk in 
people with HIV (closed circles) and in transplant recipients (open circles) to the general 
population. Estimates are for invasive cancers. Circles indicate point estimates and lines 
indicate 95% confidence intervals. Results are shown on a logarithmic scale.
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Table 1
Characteristics of cancer cases in the HIV/AIDS Cancer Match Study and Transplant Cancer Match Study.
HIV-infected Transplant Recipient
Yes, % No, % Yes, % No, %
Total 8,411 4,471,704 7,322 6,435,000
Sex
  Male 73.2 49.3 65.5 49.4
  Female 26.8 50.7 34.6 50.7
Race
  White 47.0 85.0 78.4 84.2
  Black 51.7 11.4 15.3 10.8
  Other 1.3 3.7 6.3 5.1
Age, years
  <30 2.7 1.6 0.9 1.4
  30–49 53.0 13.4 15.8 13.4
  50–69 41.7 44.2 67.8 45.0
  70+ 2.6 40.8 15.6 40.2
Cancer site
  Oral cavity/pharynx 6.2 2.7 6.6 2.7
  Stomach 1.5 1.9 2.2 2.0
  Colorectal 8.2 13.5 9.1 13.2
  Anus 20.9 0.4 2.0 0.5
  Liver 5.8 1.2 1.1 1.4
  Pancreas 1.8 2.5 2.5 2.7
  Lung 24.4 16.1 19.9 15.6
  Melanoma 2.9 6.0 7.4 6.0
  Female breast 5.1 20.6 9.0 20.4
  Cervix 9.5 2.5 1.3 2.1
  Uterus 0.5 3.3 1.5 3.5
  Prostate 8.2 18.3 16.9 18.3
  Bladder 1.5 5.4 5.0 5.4
  Kidney 2.7 3.5 12.0 3.6
  Thyroid 1.1 2.2 3.7 2.6
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